Frangione B. (1986) In vitro formation of amyloid fibrils from
two synthetic peptides of different lengths homologous to Alzheimer'sdisease beta-protein. Biochem. Biophy,s. Re,s. Commun.
141, 782—789.
Ellison D. W., Beal M. F., and Martin J. B. (1987) Phosphoethanolamine and ethanolamine are decreased in Alzheimer's disease
and Huntington's disease. Brain Re,s. 417, 389—392.
Esch F.S., Keim P. S., Beattie E. C., Blacher R. W., CuIwell A. R.,
Oltersdorf I., McClure D., and Ward P. J. (1990) Cleavage
of amyloid beta peptide during constitutive processing of its
precursor. Science 248, 1122— 1124.
Esler W. P.. Stimson E. R., Ghilardi J. R., Vinters H. V., Lee J. P.,
Mantyh P. W., and Maggio J. E. (1996) In vitro growth of
Alzheimer's disease beta-amyloid plaques displays first-order
kinetics. Biochemistry 35, 749—757.
Evans K. C., Berger E. P., Cho C. 0., Weisgraber K. H., and Lansbury P. T. Jr. (1995) Apolipoprotein E is a kinetic hut not a
thcrmodynttmic inhibitor of amyloid formation: implications for
the pathogenesis and treatment of Alzheimer disease. Proc.
Nati. Acad.Sci. USA 92, 763—767.
Fraser P. E., Nguyen J. I., Surewicz W. K., and Kirschner D. A.
(1991) pH-dependent structurttl transitions of Alzheimer amybid peptides. Biophvs. J. 60, 1190—1201.
Giordano T., Pan J. B., Monteggia L. M., Holzman I. F., Snyder
S. W., Krafft 0., Ghanbari H., and Kowall N. W. (1994) Similarities between beta amyloid peptides 1—40 and 40— 1: effects
on aggregation, toxicity in vitro, and injection in young and
aged rats. Exp. Neural. 125, 175—182.
Goedert M. (1993) Iau protein and the neurofibrillary pathology of
Alzheimer's disease. Trends Nertro,sci. 16, 460—465.
Gorevic P. D., Castano E. M., Sarma R., and Frangione B. (1987)
Ten to fourteen residue peptides of Alzheimer's disease protein
are sufficient for amyloid fibril formation and its characteristic
x-ray diffraction pattern. Biochein. Biophys. Re,s. Comrnun. 147,
854—862.
I-Iaass C., Schlossmacher M. 0., Hung A. Y., Vigo-Pelfrey C., Mellon A., Ostaszewski B. L., Lieberburg I., Koo E. H., Schenk D.,
Teplow D. B., and Selkoe D. J. (1992) Amyloid beta-peptide is
produced by cultured cells during normal metabolism. Nature
359, 322—325.
Halverson K., Fraser P. E., Kirschner D. A., and Lansbury P. T.
Jr. (1990) Molecular determinants of amyloid deposition in
Alzheimer's disease: conformational studies of synthetic betaprotein fragments. Biochemistry 29, 2639—2644.
Hilbich C., Kisters-Woike B., Reed J., Masters C., and Beyreuther
K. (1991) Aggregation and secondary structure of synthetic
amyloid ~A4 peptides of Alzheimer's disease. J. Mol. Bioi.
218, 149—163.
Hilbich C., Kisters-Woike B., Reed J., Masters C. L., and Beyreuther
K. (1992) Substitutions of hydrophobic amino acids reduce the
amyloidogenicity of Alzheimer's disease beta A4 peptides. I.
Mol. B/of. 228, 460—473.
Howlett D. R.. Jennings K. H., Lee t). C., Clark MS., Brown F.,
Wetzel R.. Wood S. J., Camilleri P., and Roberts 0. W. (1995)
Aggregation state and neurotuxic properties of Alzheimer betaamyloid peptide. Neurodegeneration 4, 23—32.
Jarrett J. I. and Lansbury P. T. Jr. (1992) Amyloid fibril formation
requires a chemically discriminating nucleation event: studies
of an amyloidogenic sequence from the bacterial protein OsmB.
Biochemistry 31, 12345—12352.
JttrrettJ. I. and Lansbury P. T. Jr. (1993) Seeding “one-dimensional
crystallization” ofamyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? (`elI 73, 1055—1058.
Jarrett J. T., Berger E. P., and Lanshury P. T. Jr. (1993) The carhoxy
terminus of the beta amyloid protein is critical for the seeding
of amyloid formation: implications for the pathogenesis of Alzheimer's disease. Biochemistry 32, 4693—4697.
Joachim C. L., Morris J. H., and Selkoe D. J. (l988)Clinically diagnosed Alzheimer's disease: itutopsy results in 150 cases. Ann.
Neurol. 24, 50—56.
Kirschner D. A., Abraham C., and Selkoe D. J. (1986) X-ray diffraction from intraneuronal paired helical filaments and cxtraneu-
